Search

Displaying results 641 - 650 of 2959 in total
  1. Drug

    Dabigatran etexilate

    go.drugbank.com/drugs/DB06695
    ApprovedInvestigational

    [A177463] Dabigatran etexilate was approved by the FDA in 2010.[L6022]

  2. Indication

    Lice of the pubic area

    go.drugbank.com/conditions/DBCOND0024508
    Drugs: Permethrin · Piperonyl butoxide
  3. Drug

    Ozenoxacin

    go.drugbank.com/drugs/DB12924
    Approved

    As of December 11, 2017 the FDA approved Ferrer Internacional S.A.'

  4. Drug

    Domperidone

    go.drugbank.com/drugs/DB01184
    ApprovedInvestigationalVet approved

    A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.

    Products: DOMPERIDONE EG, Nra-domperidone
  5. Drug

    Oteracil

    go.drugbank.com/drugs/DB03209
    ApprovedInvestigational

    It functions by blocking the enzyme orotate phosphoribosyltransferase (OPRT), which is involved in the production of 5-FU. … The main active ingredient in Teysuno is [DB09256], a pro-drug of [DB00544] (5-FU), which is a cytotoxic anti-metabolite drug that acts on rapidly dividing cancer cells.

  6. Drug

    Besilesomab

    go.drugbank.com/drugs/DB13979
    Approved

    Besilesomab is a mouse monoclonal antibody labelled with the radioactive isotope technetium-99m for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis [FDA

  7. Drug

    Sonidegib

    go.drugbank.com/drugs/DB09143
    ApprovedInvestigational

    It was FDA approved in 2015 for the treatment of basal cell carcinoma.

  8. Drug

    Antihemophilic factor (recombinant), PEGylated

    go.drugbank.com/drugs/DB09329
    ApprovedInvestigational

    Antihemophilic Factor (Recombinant), PEGylated, was approved by the FDA in December 2016 as the product _Adynovate_ [FDA label]. … It has been created to increase the half-life of factor VIII, which decreases dose frequency and decreases the occurrence of bleeding events [A32067], [A32069], [FDA label].

    Products: ADYNOVATE 500®IU / VIAL, ADYNOVATE 3000 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
  9. Drug

    Nuvaxovid

    go.drugbank.com/drugs/DB15810
    ApprovedInvestigational

    [L42450,L42965] An updated formulation covering the Omicron XBB.1.5 subvariant was approved in October 2023 in the EU[L48897] and in December 2023 in Canada. … [L40548,L40553] On July 13, 2022, nuvaxovid was granted an emergency use authorization by the FDA for the prevention of COVID-19 in adults, which was expanded to include patients ≥12 years of age in August

  10. Drug

    Captopril

    go.drugbank.com/drugs/DB01197
    ApprovedInvestigational

    Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the r...

    Mixtures: CAPTOPRIL E IDROCLOROTIAZIDE HEXAL, CAPTOPRIL E IDROCLOROTIAZIDE SANDOZProducts: CAPTOPRIL EG, Nu-capto Tab 50mg